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carnosine were also detectable by HPLC in the renal cor-
tex. Finally, TauT mRNA and protein were found in all 
renal epithelial cells. In diabetic patients, CNDP1 seemed 
to be reallocated to proximal tubules. We report compelling 
evidence that the kidney has an intrinsic capacity to metab-
olize carnosine. Both CNDP1 and CARNS are expressed 
in glomeruli and tubular cells. Carnosine-synthesizing and 
carnosine-hydrolyzing enzymes are localized in distinct 
compartments in the nephron and increased CNDP1 levels 
suggest a higher CNDP1 activity in diabetic kidneys.
Keywords Carnosine · Anserine · Carnosinase (CNDP1) · 
Metabolism · Diabetic nephropathy
Introduction
Histidine-containing dipeptides such as carnosine 
(β-alanine-l-histidine) and anserine (β-alanine-l-methyl 
histidine) are stored in several tissues, with the highest 
concentrations occurring in skeletal muscle (Bex et al. 
2014). These dipeptides have several important protec-
tive functions. The best-characterized histidine-containing 
dipeptide is carnosine (Boldyrev et al. 2013; Budzen and 
Rymaszewska 2013), which plays many roles in main-
taining health, including antioxidant activity (Babizhayev 
et al. 2013; Boldyrev 1993; Mozdzan et al. 2005) and the 
ability to scavenge carbonyls (Barski et al. 2013; Negre-
Salvayre et al. 2008; Vistoli et al. 2009), inhibit glycation 
(Alhamdani et al. 2007), and inhibit angiotensin-converting 
enzymes (Hou et al. 2003; Nakagawa et al. 2006). Carnos-
ine also has several neuroprotective roles (Baek et al. 2014; 
Boldyrev et al. 2013; Zhang et al. 2011). Anserine has sim-
ilar benefits, acting as an antioxidant (Kohen et al. 1988) 
and carbonyl scavenger (Aldini et al. 2005), as well as 
Abstract Histidine-containing dipeptides like carnos-
ine and anserine have protective functions in both health 
and disease. Animal studies suggest that carnosine can be 
metabolized within the kidney. The goal of this study was 
to obtain evidence of carnosine metabolism in the human 
kidney and to provide insight with regards to diabetic 
nephropathy. Expression, distribution, and localization of 
carnosinase-1 (CNDP1), carnosine synthase (CARNS), 
and taurine transporters (TauT) were measured in human 
kidneys. CNDP1 and CARNS activities were measured 
in vitro. CNDP1 and CARNS were located primarily in dis-
tal and proximal tubules, respectively. Specifically, CNDP1 
levels were high in tubular cells and podocytes (20.3 ± 3.4 
and 15 ± 3.2 ng/mg, respectively) and considerably lower 
in endothelial cells (0.5 ± 0.1 ng/mg). CNDP1 expres-
sion was correlated with the degradation of carnosine and 
anserine (r = 0.88 and 0.81, respectively). Anserine and 
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affecting renal sympathetic nerve activity and blood pres-
sure (Tanida et al. 2010). Functional differences between 
anserine and carnosine have been reported. For exam-
ple, anserine has higher anti-radical capacity than carnos-
ine (Boldyrev et al. 2004), lacks anti-crosslinking activity 
(Hobart et al. 2004), and activates the uptake of calcium by 
mammalian mitochondria (Daniel et al. 1992).
The naturally occurring amino acid β-alanine is the rate 
limiting amino acid in the biosynthesis of histidine-con-
taining peptides. β-Alanine is internalized by specific cells 
in order to synthesize carnosine for intracellular storage. 
Previous studies found that the taurine transporter (TauT), 
which is both sodium- and chloride-dependent, is responsi-
ble for the uptake of β-alanine in renal cells (Jessen 1994; 
Jessen and Sheikh 1991).
Carnosine is synthesized by the enzyme carnosine syn-
thase (CARNS), which is present in skeletal and heart 
muscle, as well as in certain regions in the brain (Veiga-
da-Cunha et al. 2014). The gene that encodes CARNS is 
ATPGD1 (Drozak et al. 2010); however, the expression 
and distribution of this enzyme are poorly understood 
(Boldyrev et al. 2013).
In primates, carnosine is degraded predominantly by 
the enzyme carnosinase-1 (CNDP1), which is synthesized 
and secreted by the liver into the circulation; CNDP1 
is encoded by the CNDP1 gene (Teufel et al. 2003). In 
rodents, CNDP1 is absent in the circulation. CNDP1 is 
filtered into the urine and reabsorbed into tubular cells, 
which express CNDP1 within their cytosolic compartment 
(Teufel et al. 2003). Two forms of carnosinase (CNDP) are 
expressed in primates: CNDP1, which is also called serum 
carnosinase, and CNDP2, which is also called tissue car-
nosinase or cytosolic nonspecific dipeptidase (Teufel et al. 
1989).
Given its ability to scavenge reactive oxygen species, 
carnosine might be beneficial with respect to diabetic 
nephropathy (DN) (Hipkiss et al. 2001). In animal models 
with diabetes the renal protective properties of carnosine 
have been described (Ansurudeen et al. 2012; Peters et al. 
2012, 2014; Pfister et al. 2011; Riedl et al. 2011; Yay et al. 
2014). With respect to human patients, Janssen et al. (2005) 
reported that a trinucleotide repeat in the CNDP1 gene is 
associated with a differential susceptibility for developing 
DN in patients with type 2 diabetes. The number of leu-
cine repeats in the leader peptide of the pro-enzyme affects 
the efficiency of the enzyme secretion (Riedl et al. 2010), 
thereby altering the effective concentration of this enzyme 
in the circulation (Mooyaart et al. 2009).
Although the above-mentioned association with micro-
vascular diabetic complications has been supported by 
several clinical studies, understanding the underlying 
mechanism requires experimental evidence. Thus, Sau-
erhofer et al. (2007) generated a transgenic mouse that 
overexpresses human CNDP1 under the control of a liver-
specific promoter. Giving these mice oral carnosine after 
induction of diabetes altered their glucose metabolism, but 
had no significant effect on the development or progression 
of DN, even though these transgenic mice express human 
CNDP1 in their serum. These diabetic mice have increased 
renal CNDP1 activity and reduced renal histidine dipep-
tide concentrations (Peters et al. 2012), and carnosine sup-
plementation mitigates DN, reduces renal vasculopathy, 
normalizes vascular permeability (Peters et al. 2012), and 
improves wound-healing (Ansurudeen et al. 2012). In rats 
with streptozotocin-induced diabetes, carnosine treatment 
prevents apoptosis of glomerular cells and podocyte loss 
(Peters et al. 2014; Riedl et al. 2011), decreases vascular 
damage (Pfister et al. 2011), and decreases the oxidative 
damage associated with DN (Yay et al. 2014).
Based on these previously reported findings, we hypoth-
esized that the human kidney is equipped with its own sys-
tem for metabolizing carnosine. To provide a context for 
the findings obtained from rodent studies, and to test our 
hypothesis, we measured the expression level, enzyme 
activity, distribution, and storage of CNDP1, as well as 
CARNS, β-alanine uptake levels, and the distribution of 
TauT in the nephron, in human kidney tissues and in cul-
tured renal cells. We also investigated whether carnosine 
metabolism differs in DN patients.
Materials and methods
In this study, we used human kidneys tissue obtained from 
healthy donors (Eurotransplant); the donor kidneys were 
unsuitable for transplantation due to technical reasons only; 
the tissue was de-identified. The organs were collected 
between 1995 and 2012. The renal cortex and isolated glo-
meruli were used to investigate the presence of components 
involved in carnosine metabolism in the kidney and the 
compartments of the renal cortex.
Antibodies
To examine the localization of the CNDP1 protein in 
human tissue samples, we generated a polyclonal anti-
CNDP1 antibody. Two rabbits were immunized with a 
synthetic peptide corresponding to CNDP1, as described 
by Teufel et al. (2003). The serum was collected and pre-
adsorption with the synthetic peptide was used to confirm 
specificity (Supplementary Fig. 1). The monoclonal anti-
CARNS antibody was a generous gift from Prof. Frank 
L. Margolis (University of Maryland School of Medicine, 
Baltimore, MD); this antibody has been described previ-
ously (Margolis and Grillo 1984; Margolis et al. 1987). 
The specificity of the anti-CARNS antibody was confirmed 
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by performing double-staining of COS-7 cells transfected 
with a His-tagged CARNS construct; the antibody showed 
co-localization with an anti-His antibody (Supplementary 
Fig. 2). The rabbit anti-TauT antibody (raised against the 
C-terminal domain of the TauT protein, which is encoded 
by the SLC6A6 gene) was obtained from Sigma-Aldrich 
(St. Louis, MO). For negative controls, the rabbit immuno-
globulin fraction (solid-phase absorbed) and normal mouse 
serum (DakoCytomation, Glostrup, Denmark) were used at 
the same concentration as their respective primary antibody.
Immunohistochemistry and immunofluorescence
Immunohistochemistry and immunofluorescence were used 
to detect the metabolic enzymes CARNS and CNDP1, the 
localization of histidine-containing dipeptides, and the 
TauT in the kidney. For CARNS and CNDP1 immunohis-
tochemistry, the tissue sections were deparaffinized, and 
antigen retrieval was performed by incubating the sections 
with proteinase K (DakoCytomation) for 10 min at room 
temperature. Endogenous peroxidases were blocked with 
0.125 % H2O2 (v/v in distilled water) for 20 min. Immu-
nohistochemistry using the anti-TauT antibody was per-
formed as described above except, antigen retrieval was 
performed using citrate buffer. After antigen retrieval, the 
sections were incubated for 60 min with primary antibod-
ies against CARNS, CNDP1, or the TauT. After washing 
with PBS, the sections were incubated with the following 
secondary antibodies: anti-mouse Envision (DakoCytoma-
tion) conjugated with HRP (for anti-CARNS) or anti-rab-
bit Envision (DakoCytomation) conjugated with HRP (for 
anti-CNDP1 and anti-TauT). HRP was visualized by incu-
bation with DAB+ substrate solution (DakoCytomation) for 
10 min. The nuclei were counterstained with hematoxylin.
Double-label immunofluorescence was used to distin-
guish between the distal and proximal tubules. Tamm-
Horsfall was used as a marker of distal tubules. Sections 
were incubated with anti-CARNS and anti-Tamm-Horsfall 
and sections were incubated with anti-CARNS and anti-
CNDP1 for 60 min. The following secondary antibodies 
were used: Alexa Fluor 488 donkey anti-goat IgG, Alexa 
Fluor 546 goat anti-mouse IgG, and Alexa Fluor 488 goat 
anti-rabbit IgG (all obtained from Life Technologies, Grand 
Island, NY). As a negative control, the primary antibodies 
were replaced with normal mouse serum (DakoCytoma-
tion) and rabbit immunoglobulin fraction (DakoCytoma-
tion) at the same concentration as their respective primary 
antibody (Supplementary Fig. 3).
Cultured cells
Cultured cells from various compartments of the kid-
ney were used to examine the cell-specific distribution of 
carnosine metabolic enzymes. SV40 immortalized human 
podocytes were used to measure mRNA levels. For meas-
uring protein activity, we used conditionally immortal-
ized mouse podocytes generated from the ImmortoMouse 
(Charles River, Wilmington, MA) (Weins et al. 2001). 
Differentiation was induced by growing mouse podo-
cytes ≥10 days on collagen type I (BD Biosciences, Bed-
ford, MA) under permissive conditions at 33 °C with 
interferon-γ (10 U/ml; Roche Diagnostics, Mannheim, 
Germany) or under non-permissive conditions at 37 °C 
without interferon-γ. Podocytes and HK2 tubular epithelial 
cells (CRL-2190, American Type Culture Collection) were 
cultured in RPMI 1640 medium (Gibco, Life Technologies, 
Darmstadt, Germany) supplemented with 10 % FCS (Bio-
chrom GmbH, Berlin, Germany) and penicillin/streptomy-
cin (1 % for HK2 cells and 2 % for podocytes; Biochrom 
GmbH). Early-passage-number (passage number 8–15) 
human umbilical vein endothelial cells (HUVEC) were cul-
tured in fetal calf serum containing endothelial cell growth 
supplement, epidermal growth factor, heparin, hydrocorti-
sone, and 1 % penicillin/streptomycin in accordance with 
the manufacturer’s instructions (PromoCell GmbH, Hei-
delberg, Germany). All cells were cultured at 37 °C in 5 % 
CO2 and harvested by adding 60 µl pre-lysis buffer contain-
ing 20 mM Tris/HCl (pH 8.0), 150 mM NaCl, 20 mM NaF, 
1 % Triton X-100, 2 mM EDTA, 1 mM EGTA (all obtained 
from Sigma-Aldrich) (Complete Mini, Roche Diagnostics).
mRNA quantification by RT‑PCR
mRNA was isolated from the whole human kidney cortex 
samples, isolated glomeruli, SV40 immortalized human 
podocytes, HUVEC cells, and cultured tubular epithelium 
(HK2) cells, after which ATPGD1 (which encodes the 
CARNS protein) and CNDP1 mRNA levels were quanti-
fied using RT-PCR. SYBR Green quantitative PCR was 
performed to quantify the levels of ATPGD1 and CNDP1 
mRNA. All cDNA samples were amplified in duplicate. The 
following primers were used to amplify ATPGD1 mRNA: 
forward, GAAGCTGGAGGAGGAGGAG; reverse, GTG-
GCCTATCACCCTGTGTC. The following primers were 
used to amplify CNDP1 mRNA: forward, TTCAATC-
CGTCTAGTCCCTCACATG; reverse, TGCAATC-
CACGGGTGTAGTCC. The amplified mRNA levels were 
normalized to the expression levels of the housekeeping 
genes GAPDH and HPRT as described by Baelde et al. 
(2004).
Carnosinase protein concentration
CNDP1 protein concentration was measured using a 
modified ELISA assay (Adelmann et al. 2012). In brief, 
highly absorbent microtiter plates (Greiner Labortechnik, 
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Frickenhausen, Germany) were coated with 100 µl goat 
polyclonal anti-human CNDP1 (10 µg/ml; R&D Systems, 
Wiesbaden, Germany); purified rabbit anti-CNDP1 IgG 
(Atlas, Abcam, Cambridge, United Kingdom) was used to 
detect bound CNDP1. A biotinylated goat anti-rabbit IgG 
was added, followed by avidin-HRP. Deep-blue peroxidase 
(POD; Roche Diagnostics) was used for color development, 
and the plates were read immediately at 450 nm. Recom-
binant human CNDP1 (R&D Systems, Minneapolis, MN) 
was used as a standard; CNDP1 protein concentrations were 
measured in the linear part of the dilution curve. The sensi-
tivity of the ELISA assays was approximately 15 ng/ml.
Anserine and carnosine concentrations
Anserine and carnosine concentrations were measured 
fluorometrically using high-performance liquid chroma-
tography as previously described (Schönherr 2002). Frozen 
kidney tissue was homogenized in cold buffer containing 
20 mM HEPES, 1 mM ethylene glycol-tetraacetic acid 
(EGTA), 210 mM mannitol and 70 mM sucrose per gram 
tissue, pH 7.2. The homogenate was centrifuged at 1500×g 
for 5 min at 4 °C, and the supernatant was kept at −80 °C 
until analysis. The kidney homogenate and the homog-
enized cells were diluted with sulfosalicylic acid in order to 
precipitate the proteins. After the samples were derivatized 
using carbazole-9-carbonyl chloride, they underwent liquid 
chromatography and quantification using fluorescence. The 
retention time of each component was determined by spik-
ing the sample with purified l-carnosine or anserine. All 
samples were measured at least twice, and one sample was 
spiked with the standards to identify each analyte. The reli-
ability of the method was 0.91.
Carnosinase and carnosine synthase activity
CNDP1 activity was assayed as described previously 
(Peters et al. 2010; Teufel et al. 2003). In brief, the reaction 
was initiated by the addition of carnosine to cell homogen-
ates at pH 7. The reaction was terminated at pre-determined 
intervals by adding 1 % trichloroacetic acid. Liberated 
histidine was derivatized by adding o-phthalaldehyde, and 
fluorescence was read using a MicroTek plate reader (λEx: 
360 nm; λEm: 460 nm). To avoid nonspecific CNDP2 activ-
ity, Bestatin (Sigma-Aldrich, St. Louis, MO) was added 
to block the activity of CNDP2. Addition of Bestatin did 
not affect carnosine or anserine degradation, showing 
that CNDP2 was not active in our experiments. Vmax val-
ues were obtained from at least three separate assays by 
fitting the Dixon plots using a linear regression program. 
The kinetic parameters were determined using various con-
centrations of substrates, and the data were fit using the 
Michaelis–Menten equation.
CARNS activity was determined by measuring the 
incorporation of radiolabeled β-alanine into carnosine 
(Drozak et al. 2010). In brief, the reaction was initiated by 
the addition of [3H]-alanine to cell homogenates. The cell 
homogenate was then separated by HPLC, and radioac-
tive carnosine was measured using a scintillation counter 
(Beckman).
CNDP1 protein in DN patients
For the investigation of the role of carnosine metabolism 
in relation to renal disease, we used biopsies from patients 
with type 2 diabetes and DN (N = 14) and compared 
them to healthy controls (N = 7) (Baelde et al. 2007). The 
CNDP1 staining was scored by intensity degrees between 
0 and 2.
Statistical analysis
A minimum of three independent experiments were per-
formed in duplicate. All summary data are provided as 
mean ± SD. To compare ≥3 groups, a one-way analysis 
of variance was performed, followed by post hoc analy-
ses using Tukey’s test. For the intensity analysis to com-
pare diabetic patients with controls we used an independent 
Student t test. All statistical analyses were performed using 
SPSS, version 20.0 (IBM, Armonk, NY).
Ethical considerations
All tissue samples were coded, then handled and analyzed 
anonymously in accordance with the ethical principles 
stated in the Declaration of Helsinki.
Results
CNDP1
Immunohistochemistry showed that the CNDP1 protein 
is localized primarily in the distal tubules and in the glo-
meruli (Fig. 1a). Next, we measured the mRNA levels, 
protein levels, and enzyme activity of CNDP1 in human 
kidney samples and cultured cells. The relative transcrip-
tion levels were highest in the human kidney (1.00 ± 1.12 
relative units), glomeruli (0.802 ± 1.1), whereas extremely 
low levels of CNDP1 mRNA were detected in HUVEC 
cells (0.001 ± 0.0013) and HK2 cells (0.000185) (Fig. 2). 
In immortalized podocytes the relative transcription 
was also high (0.016 ± 0.013). Consistent with this rank 
order of CNDP1 expression, CNDP1 protein levels were 
high in immortalized podocytes (15 ± 3.2 ng/mg pro-
tein) and low in HUVEC cells (0.5 ± 0.1 ng/mg protein); 
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interestingly, CNDP1 protein levels were high in HK2 
cells (20.3 ± 3.4 ng/mg protein). CNDP1 activity reflected 
high catabolic rates of carnosine and anserine in podo-
cytes (2.8 ± 1.7 and 2.9 ± 1.5 nmol/mg/h, respectively) 
and tubular cells (2.6 ± 0.2 and 3.9 ± 0.4 nmol/mg/h, 
respectively) and low carnosine and anserine catabolic 
rates in HUVEC cells (1.3 ± 0.4 and 0.05 ± 0.08 nmol/
mg/h, respectively) (Fig. 3). Both, CNDP1 protein levels 
and CNDP1 enzyme activities were correlated to carnosine 
(r = 0.88) and anserine (r = 0.81) degradation.
CARNS
Immunohistochemistry revealed that CARNS protein was 
primarily localized close to the apical membrane of the 
proximal tubules, as well as in the glomeruli [albeit at 
low levels (Fig. 1b)]. Double-label immunofluorescence 
for CARNS and Tamm-Horsfall protein showed a lack 
of co-localization, indicating that CARNS is not present 
in distal tubules. Immunofluorescence revealed a lack of 
co-localization between CNDP1 and CARNS, as CARNS 
is localized primarily in proximal tubules (Fig. 1c, d). 
CARNS mRNA was detected in human kidney samples, 
(1.00 ± 0.63 relative units), glomeruli (0.4136 ± 0.08), 
and tubular cells (0.035 ± 0.005) (Fig. 4). CARNS 
mRNA levels were also high in the immortalized podo-
cyte cell line (1.07 ± 0.15) but were low in the HK2 
(0.035 ± 0.005) and HUVEC (0.032 ± 0.02) cells. To 
examine whether β-alanine affects CARNS activity in 
the cell lines, HK2 cells were treated with β-alanine. This 
Fig. 1  a Immunohistochemistry showing the presence of CNDP1 
in the glomeruli and distal tubules (arrows). b Immunohistochemis-
try showing CARNS expression in proximal tubules and glomeruli 
(arrows). The nuclei were counterstained with hematoxylin. c Immu-
nofluorescence showing carnosinase (red) and carnosine synthase 
(green) in separate compartments in tubular cells. Immunohistochem-
istry showing CARNS expression in proximal tubules and glomeruli 
(arrows). d Immunofluorescence showing non-overlapping expres-
sion of CARNS (red) in the proximal tubules and Tamm-Horsfall pro-
tein (green) in the distal tubules. e Immunohistochemistry showing 
that the TauT is expressed in proximal tubules (red arrow) and distal 
tubules (black arrow) in human kidney samples. The highest proteins 
levels were present in the distal tubules. The nuclei were counter-
stained with hematoxylin
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treatment did not increase CARNS activity in the cells. 
In normal individual kidney samples, we found relatively 
high variation of CNDP1 and CARNS levels. Despite 
this variation, we found a strong positive correlation 
between CNDP1 and CARNS mRNA levels in individual 
samples (r = 0.81), suggesting that the expression levels 
of CNDP1 and CARNS are controlled by a similar path-
way (Fig. 5).
Histidine‑containing dipeptides
We next measured the concentrations of histidine-con-
taining dipeptides using high-performance liquid chro-
matography (HPLC). Repeated measurement of samples 












































Fig. 2  CDNP1 mRNA was amplified from human kidney sam-
ples (1.00 ± 1.12) (N = 8), human glomeruli (Glom) (0.802 ± 1.1) 
(N = 8), immortalized human podocytes (0.016 ± 0.0013) (N = 2), 
human endothelial cells (HUVEC) (0.001 ± 0.0013) (N = 5), and 
human proximal tubular epithelial cells (HK2 cells) (0.000185) 
(N = 1). All values were normalized to the mean value obtained from 
the human kidney samples. Note that the y-axis is plotted on a loga-






























Catabolic rate of carnosine
Catabolic rate of anserine
Fig. 3  CNDP1 activity (in nmol/mg/h) was measured as the rate 
of degradation of carnosine (black) and anserine (grey) in mouse 
podocytes (2.8 ± 1.7 and 2.9 ± 1.5 nmol/mg/h, respectively) and 
human proximal tubular epithelial cells (HK2 cells) (1.3 ± 0.4 and 











































Fig. 4  CARNS mRNA was amplified from human kidney samples 
(1.00 ± 0.63) (N = 8), glomeruli (Glom) (0.4136 ± 0.08) (N = 4), 
immortalized human podocytes (1.07 ± 0.15) (N = 2), human 
endothelial cells (HUVEC) (0.032 ± 0.02) (N = 5), and proximal 
tubular epithelial cells (HK2 cells) (0.035 ± 0.005) (N = 2). All val-
ues were normalized to the mean value obtained from the human kid-
ney samples. Note that the y-axis is plotted on a logarithmic scale, 
expressed as mean ± SD of relative units
























Fig. 5  Relative CARNS mRNA level is plotted against the relative 
CNDP1 mRNA level measured in human kidney samples. Each data 
point represents a separate sample. The solid line is a linear fit of the 
data. r = 0.81 (N = 13)
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with a mean of 4 nmol/mg anserine and a standard devi-
ation of 2.7 [95 % CI 2.3–6.4] and a mean of 1.8 nmol/
mg carnosine and a standard deviation of 0.9 [95 % CI 
1.1–2.8] (Fig. 6). Thus, human renal tissue contains 
more anserine than carnosine. Anserine and carnos-
ine were also present in the cultured podocytes but the 
concentration varied strongly with concentrations of 
2.1–13.8 nmol anserine/mg [95 % CI] and 1.7–8.1 nmol 
carnosine/mg protein [95 % CI], whereas in tubu-
lar cells lower amount of carnosine could be detected 
(0.2 nmol/mg protein) and anserine was below detection 
limit.
Taurine transporter
The TauT transports β-alanine into cells. Immunohistochemis-
try revealed that the TauT is present in glomerular cells and on 
the membranes of all renal tubules (Fig. 1e). These data were 
supported by mRNA measurements (data not shown). Treat-
ing HK2 cells dose-dependently (0.1–5 mM) with β-alanine 
for 24 and 48 h had no effect on the expression of TauT (data 
not shown).
CNDP1 protein of DN patients
We also compared diabetic patients with DN (N = 14) to 
controls (N = 7) by scoring the intensity of CNDP1 immu-
nostaining of renal tissue. In the tubules, we found a signif-
icant difference between DN patients and controls (Fig. 7). 
The higher levels of CNDP1 in DN patients in the proximal 
tubules could indicate increased hydrolysis of carnosine 


























Fig. 6  Concentrations of anserine (4 ± 2.7) [95 % CI 2.3–6.4] and 
carnosine (1.8 ± 0.9) [95 % CI 1.1–2.8] in human kidney samples 
(N = 3) measured using HPLC, expressed as mean ± SD
Fig. 7  CNDP1 in diabetic 
patient (N = 14) and control 
(N = 7). Immunohistochem-
istry and intensity score 
*(p = 0.029). It shows a 
reallocation of CNDP1 from 
distal to proximal tubules in 
diabetic patients with renal 
damage. a Healthy control 
(0.857 ± 0.8997), b dia-
betic nephropathy patients 
(1.171 ± 0.726), c negative 
control, d intensity stain-
ing difference; red arrow 
proximal tubules, black arrow 
distal tubules; expressed in 
mean ± SD
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the proximal tubules as a result of reabsorption of CNDP1 
caused by proteinuria in patients with DN.
Discussion
This study provides the first evidence that the human kid-
ney has an intrinsic system for metabolizing carnosine. 
In addition, we investigated the relation of CNDP1 pro-
tein to DN in humans. Combining several experimental 
approaches, we found that the proteins involved in carnos-
ine metabolism are located in distinct compartments within 
the nephron. The presence of metabolizing enzymes and 
the presence of stored histidine-containing dipeptides sup-
ports our hypothesis of kidney-specific carnosine metabo-
lism. The staining intensity of CNDP1 was significantly 
higher in the renal tubules of patients with DN, and immu-
nohistochemistry revealed that CNDP1 was reallocated to 
the proximal tubules.
We compared the amount of carnosine in the kidney to 
that in the skeletal muscles fibers, which have the highest 
concentration of carnosine in the human body. The carnos-
ine concentration determined in human muscles was com-
pared to that in the human kidney. The renal concentrations 
of anserine (1.1–7.4 mmol/kg for anserine) almost reach 
the levels of the carnosine concentration of the skeletal 
muscles (7.2–30.7 mmol/kg dry muscle mass), suggesting 
that carnosine metabolism plays an important role in main-
taining normal kidney function, consistent with the protec-
tive properties of carnosine in the muscle. The range of car-
nosine and anserine concentrations in cultured podocytes 
differed, and were probably based on the passage number 
of the cells and culturing conditions.
One of the kidney’s primary functions is to remove and 
detoxify low-molecular weight compounds. Several stud-
ies reported a difference between the protective properties of 
anserine and carnosine (Boldyrev et al. 2004; Daniel et al. 
1992; Hobart et al. 2004). For example, anserine has a higher 
anti-radical capacity and more antioxidant properties than car-
nosine; therefore, we hypothesize that anserine protects renal 
function against the detrimental effects of oxygen radicals.
The podocytes and proximal tubules provide the first line 
of defense after the fenestrated endothelium. We hypoth-
esize that in these structures, CARNS is required to main-
tain sufficient anserine concentrations, thereby supporting 
their protective function. The exchange of protons with 
K+ and Na+ ions requires continuous low pH in the distal 
tubules. Because carnosine has high pH buffering capacity, 
carnosine must be removed from the distal tubules, thereby 
explaining the high concentration of CNDP1 in this renal 
compartment. Teufel et al. (1989) reported high levels of 
CNDP1 in the stomach epithelium, a site that also requires 
an extremely low pH.
Next, we found that the TauT is present in the mem-
branes of all renal tubular cells. Taurine and β-alanine com-
pete for binding to TauT (Liu et al. 1992). In the proximal 
tubules, CARNS synthesizes carnosine from β-alanine and 
histidine. Therefore, TauT is believed to stimulate the inter-
nalization of β-alanine primarily in the proximal tubular 
epithelium. Because taurine is an osmolyte, the expression 
of TauT in the distal tubules is regulated by osmolar stress 
(Chesney et al. 2010) (Fig. 1e). The gene that encodes TauT 
is regulated by a complex interplay between transcription 
factors and response elements (Chesney et al. 2010). Over 
time, β-alanine can deplete taurine from tissues, including 
renal tissue, thereby upregulating the synthesis and activ-
ity of TauT. However, applying β-alanine to HK2 cells did 
not increase carnosine levels, nor did it appear to induce the 
expression of either CARNS or the TauT, possibly because 
the level of TauT protein in the membrane is static.
Although we found clear evidence of organ-specific 
carnosine metabolism in the kidney and found CNDP1 
changes in DN conditions, this study had some limita-
tions. HUVEC cells, podocytes, and HK2 cells were used 
to investigate the specific locations of the mRNA levels and 
enzyme activities in the glomeruli. It is possible that when 
these cell lines were created, they lost part of their original 
expression profile. Future studies could focus on knockout 
models with segment specific genetic manipulation.
Considering the physiological function of podocytes in 
glomerular homeostasis, the high levels of mRNA, pro-
teins, and enzyme activities measured in immortalized 
podocytes suggest that carnosine metabolism plays a role 
in glomerular function. In endothelial cells, CNDP1 protein 
and activity levels were consistently low both in vitro and 
in vivo; therefore, endothelial cells likely play only a minor 
role in carnosine metabolism in the kidney. The levels of 
cell type-specific carnosine and anserine degradation by 
CNDP1 in renal cells were closely correlated with CNDP1; 
in other cells, factors such as allosteric conformation and 
substrate inhibition play a role (Peters et al. 2010, 2011). 
Interestingly, significant levels of anserine and carnosine 
were present in the human kidney tissue samples; in con-
trast, their levels were much lower in the cultured cells, 
possibly due to low CARNS activity, high CNDP1 activity, 
intracellular degradation, and/or high turnover.
Our results on DN patients are in line with several stud-
ies, which reported that carnosine might play a role in the 
pathogenesis of DN (Janssen et al. 2005; Sauerhofer et al. 
2007). In this respect, diabetic podocyte-specific condi-
tional knockout mice should be developed; these mice 
would shed light on the role of CNDP1 and CARNS in the 
glomerulus. Future studies could focus on the regulation of 
transcription levels, uptake in tubular cells of CNDP1 in 
DN and investigate whether the histidine-containing dipep-
tide concentrations are decreased in diabetic state. Also, 
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studies should focus on the role of β-alanine in renal health 
and disease. In addition, it would be extremely interest-
ing to determine whether diabetes-related oxidative stress 
changes carnosinase activity in the kidney. In this respect, 
manipulating renal carnosine metabolism may provide 
novel therapeutic options for treating DN.
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